Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors
AssigneeMemorial Sloan Kettering Cancer Center
InventorsLiang Deng, Jedd Wolchok, Taha Merghoub, Stewart Shuman, Peihong Dai, Weiyi Wang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to modified vaccinia Ankara (MVA) virus or MVAΔE3L delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor.
Claims13
A method of eliciting an immune response in a subject with a solid malignant tumor, the method comprising delivering to the tumor cells a therapeutically effective amount of a modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L).
A method of eliciting an immune response in a subject with a solid malignant tumor, the method comprising delivering to the tumor cells of the subject a therapeutically effective amount of a modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L), and conjointly administering to the subject a therapeutically effective amount of an immune checkpoint blocking agent or an immune checkpoint agonist.
Dependencies are inferred from the claim text.